The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
 
Ana Baramidze
Travel, Accommodations, Expenses - Regeneron
 
Miranda Gogishvili
No Relationships to Disclose
 
Tamta Makharadze
No Relationships to Disclose
 
Mariam Zhvania
No Relationships to Disclose
 
Khatuna Vacharadze
No Relationships to Disclose
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - AstraZeneca; MSD Oncology; Pfizer; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - Pfizer
Research Funding - BMS GmbH & Co. KG (Inst); MSD Oncology (Inst); Novartis (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Astrazeneca; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Regeneron; Roche
 
Tamar Melkadze
No Relationships to Disclose
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Repertoire Immune Medicines; Rootpath
Consulting or Advisory Role - Adagene; Adaptimmune; Agenus; Alligator Bioscience; AnaptysBio; AstraZeneca/MedImmune; Biond Biologics; BioNTech; Bristol-Myers Squibb; Dragonfly Therapeutics; Genocea Biosciences; Gilead Sciences; immunocore; Innate Pharma; Iovance Biotherapeutics; ITeos Therapeutics; Jazz Pharmaceuticals; Kadmon; Kanaph Therapeutics; Merck; Molecular Partners; Numab; Ocellaris Pharma; OncoSec; Pfizer; Pierre Fabre; PIOtx; Pliant; Regeneron; Sapience Therapeutics; Seagen; Simcha Therapeutics; Simcha Therapeutics; ST Cube; Targovax; Tessa Therapeutics; Turnstone Bio; Verastem; Xilio Therapeutics
Other Relationship - CEC Oncology; Physicans' Education Resource
 
Hector Martinez-Said
Employment - RiboNexus
Leadership - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche; Sanofi; Sun BioPharma
 
Jayakumar Mani
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Usman Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Mark Salvati
Employment - Amgen; Regeneron
Stock and Other Ownership Interests - Amgen; Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Giuseppe Gullo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron